Melatonin Use in Pediatrics: Evaluating the Discrepancy in Evidence Based on Country and Regulations Regarding...

Area of Science:

• Pediatric pharmacology
• Supplement regulation
• Evidence-based medicine

Background:

• U.S. manufacturers are producing melatonin supplements for pediatric use.
• Melatonin regulation varies globally, with minimal oversight for U.S. over-the-counter (OTC) supplements.
• Most pediatric melatonin studies involve children with comorbidities like autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD).

Purpose of the Study:

• To critically evaluate the evidence for pediatric melatonin use.
• To assess the impact of clinical trial location and national regulations on melatonin product evidence.
• To determine the safety and efficacy of U.S. melatonin formulations in children.

Main Methods:

• Literature review of pediatric melatonin studies.
• Analysis of regulatory frameworks for melatonin supplements in different countries.
• Evaluation of study populations, focusing on comorbidities.

Main Results:

• No existing evidence supports the use of U.S. melatonin formulations in healthy children.
• The majority of trials focus on pediatric populations with specific health conditions.
• U.S. melatonin products face the least stringent regulatory oversight globally.

Conclusions:

• U.S. melatonin products lack sufficient safety and efficacy data for healthy pediatric use.
• Given regulatory gaps and limited evidence, cautious or no use of these supplements is advised for healthy children.
• Further research is needed to establish safety and efficacy in the pediatric population, especially for U.S. products.